METHODS: Four sensitivity scenarios were explored to identify cases of MF. Point prevalence and cumulative incidence of MF were determined as of December 31, 2021, and within 2021, respectively. A cross-sectional analysis used the main scenario definition of MF to identify cases and evaluate the period prevalence of patients receiving treatment for symptoms and/or splenomegaly, including first-line (1L) Janus kinase inhibitor (JAKi), second-line, or further (2L+) MF-related treatment therapies during 2021. The prevalence of anemia treatment was also reported.
RESULTS: The estimated standardized point prevalence of MF on December 31, 2021, was 9.9-12.4 cases per 100 000 persons, and cumulative incidence in 2021 was 1.2-1.8 cases per 100 000 persons. Standardized period prevalence in 2021 for MF patients receiving 1L JAKi and/or 2L+ MF-related treatment was 4.0 cases per 100 000. Among these patients, 47.1%-53.7% required treatment for anemia, resulting in a period prevalence of 1.9-2.2 cases per 100 000 individuals.
CONCLUSIONS: The data reveal gaps in MF treatments and the need to improve patient quality of life.
方法:探索了四种敏感性情景来识别MF病例。MF的点患病率和累积发病率分别于2021年12月31日和2021年内确定。横断面分析使用MF的主要情景定义来识别病例并评估接受症状和/或脾肿大治疗的患者的时期患病率。包括一线(1L)Janus激酶抑制剂(JAKI),第二行,或2021年进一步的(2L+)MF相关治疗疗法。还报道了贫血治疗的患病率。
结果:2021年12月31日估计的MF标准化点患病率为每10万人9.9-12.4例,2021年的累计发病率为每10万人1.2-1.8例。2021年接受1LJAKI和/或2L+MF相关治疗的MF患者的标准化期患病率为4.0例/10万。在这些患者中,47.1%-53.7%的贫血需要治疗,导致每10万人中1.9-2.2例。
结论:数据揭示了MF治疗的差距和改善患者生活质量的需要。